S 4340 United States Senate · 117th Congress

EFFECTIVE Act

Summary
Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act or the EFFECTIVE Act This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug upon a determination that the drug does not provide a significant advantage or clinical superiority compared to other drugs.
Bill status in committee 1 of 4 stages cleared
Introduction
May 2022
Committee Review
Floor Vote
President
Introduced May 26, 2022 Last action May 26, 2022
Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
2
Key actions
0
Committee
1
May 26, 2022
Committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
upper
May 26, 2022
Introduced
Introduced in Senate
upper
1 primary · 1 co-sponsor

Sponsors